论文部分内容阅读
目的评价呼吸兴奋剂多沙普仑联合双水平正压通气(BIPAP)治疗慢性阻塞性肺疾病急性加重期(AECOPD)分并Ⅱ型呼吸衰竭患者,方法将76例慢性阻塞性肺疾病急性加重期(AECOPD)合并呼吸衰竭患者分为治疗组41例和对照组35例,双组均给予常规药物治疗,治疗组同时给予BIPAP呼吸机无创通气治疗及新型兴奋剂多沙普仑静脉点滴,对两组患者心率、呼吸频率、血气分析进行比较。结果治疗组患者心率、呼吸频率、血气分析的改善情况优于对照组,两组比较差异有统计学意义(P<0.05)。结论多沙普仑联合BIPAP无创通气对AECOPD伴呼吸衰竭患者诊疗效果肯定,比单用BIPAP治疗病情清醒状态时间长,二氧化碳潴留情况改善快,缩短治疗时间,减少并发症发生。
Objective To evaluate the efficacy and safety of doxapram combined with double-level positive pressure ventilation (BIPAP) in the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and type Ⅱ respiratory failure.Methods 76 patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients with respiratory failure were divided into treatment group (n = 41) and control group (n = 35). The patients in both groups were given conventional medical therapy. The patients in treatment group were given BIPAP ventilator noninvasive ventilation and doxorubicin intravenously. Group heart rate, respiratory rate, blood gas analysis were compared. Results The improvement of heart rate, respiratory rate and blood gas analysis in the treatment group was better than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion Doxapram combined with BIPAP has a positive effect on diagnosis and treatment of patients with AECOPD and respiratory failure. Compared with BIPAP alone, the condition of arousal is prolonged, carbon dioxide retention is improved rapidly, the treatment time is shortened and the complication rate is reduced.